Dapagliflozin-13C6 (BMS-512148-13C6) is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury[2].
Molecular Weight:
414.83
Formula:
C1513C6H25ClO6
Target:
Isotope-Labeled Compounds
Application Notes:
MCE Product type: Isotope-Labeled Compounds
* VAT and and shipping costs not included. Errors and price changes excepted
